Switching cell-penetrating peptides from "deliverer" to "enforcer" by hydrophobic amino acid end-tagging to combat intracellular bacterial infections.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42485874.
- Also identified by DOI 10.1016/j.biomaterials.2026.124473.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The presence of recalcitrant intracellular bacteria (ICB) and antimicrobial resistance poses a significant challenge to global public health. Antimicrobial peptides (AMPs) and cell-penetrating peptides (CPPs) play irreplaceable roles in combating multidrug-resistant (MDR) bacteria and drug delivery, respectively, but how to combine the advantages of both to design peptide-based biomaterials to fight ICB is still a formidable challenge. Here we constructed a miniature peptide library containing thirty AMPs with dual functions of antimicrobial and cell-penetrating properties based on CPP transactivator of transcription (Tat) by combining the end-tagging and structure-activity relationship of AMPs. The lead peptide, 5VT, identified by screening of a peptide library, exhibited potent activity, including against clinically isolated drug-resistant strains, while also demonstrating excellent biocompatibility. Strikingly, 5VT efficiently penetrates cells primarily through clathrin-mediated endocytosis and macropinocytosis, and is capable of eradicating intracellular Salmonella typhimurium and alleviating inflammatory responses. Additionally, 5VT kills bacteria primarily through employing a dual mechanism that involves attacking bacterial cell membranes and triggering abnormal production of reactive oxygen species. Further in vivo analysis showed that 5VT was non-systemically toxic and exhibited substantial therapeutic capacity in a peritonitis-sepsis model. We provide a simple and efficient strategy for transforming cationic CPPs from "deliverers" to "all-purpose warriors" to fight ICB, which provides new insights into the design and development of peptide-based antimicrobial materials to deal with the increasing prevalence of intracellular bacterial and MDR bacteria.